Document is current
Any future updates will be listed below
-
Authors
de la Rocha, Carmen
Cid-López, Marco A.
Venegas-López, Blanca I.
Gómez-Méndez, Sandra C.
Sánchez-Ortiz, Adriana
Pérez-Ríos, Alma M.
Llamas-Velázquez, Ricardo A.
Meza-Acuña, Aidé I.
Vargas-Íñiguez, Bárbara
Rosales-Galván, Daniela
Tavares-Váldez, Alejandra
Luna-Gudiño, Nizdali
Hernández-Puente, Cinthia V.
Milenkovic, Jovana
Iglesias-Palomares, Cecilia
Méndez-del Villar, Miriam
Gutiérrez-Dieck, Gerardo A.
Valderrábano-Roldán, Carlos G.
Mercado-Cerda, Jennefer
Robles-Bojórquez, Jocelyn G.
Mercado-Sesma, Arieh R. https://orcid.org/0000-0002-9025-9328
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04407507 at ClinicalTrials.govDocuments that mention this clinical trial
Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial
https://doi.org/10.1186/s12879-022-07890-6
- License Information
-
More Information
Article History
Received: 13 May 2022
Accepted: 21 November 2022
First Online: 8 December 2022
Declarations
:
: The protocol was approved by the local ethics, biosafety and investigation committees and the Mexican health ministry COFEPRIS: 203301410A0055. The study is registered on ClinicalTrials.gov: NCT04407507. Patients gave their written consent prior the participation on the study and informed consent was obtained from all the participants.
: Not applicable.
: The authors declare that they have no competing interests.
